Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation.

Autor: REILLY, M. C., BARGHOUT, V., MCBURNEY, C. R., NIECKO, T. E.
Předmět:
Zdroj: Alimentary Pharmacology & Therapeutics; Sep2005, Vol. 22 Issue 5, p373-380, 8p
Abstrakt: : Tegaserod is a promotility agent with proven efficacy and safety in patients with irritable bowel syndrome with constipation. : To assess tegaserod's effect on work productivity and daily activity. : Women, 18–65 years old and meeting Rome II criteria for irritable bowel syndrome with constipation, were randomized to a double-blind, placebo-controlled, multicentre study of tegaserod 6 mg b.d. or placebo. Productivity loss and daily activity impairment because of irritable bowel syndrome were measured with the Work Productivity and Activity Impairment questionnaire for irritable bowel syndrome, modified to exclude diarrhoea as a symptom. Assessments were made at baseline, weeks 2 and 4. : A total of 2660 women were randomized and, of these, 1675 [tegaserod ( n = 1363), placebo ( n = 312)] were employed and completed Work Productivity and Activity Impairment for irritable bowel syndrome questionnaires. Compared with placebo, tegaserod significantly reduced work and daily activity impairment at weeks 2 and 4. Tegaserod reduced absenteeism by 2.6% ( P = 0.004), presenteeism by 5.4% ( P < 0.0001), overall work productivity loss by 6.3% ( P < 0.0001), and activity impairment by 5.8% ( P < 0.0001) at week 4 (vs. baseline). Assuming a 40-h workweek, tegaserod reduced work productivity loss by 2.5 h/week. : Tegaserod significantly reduced work productivity loss and daily activity impairment at 2 weeks, and this benefit was maintained at 4 weeks. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje